Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi)
- Elizabeth Dudnik*
- , Elias Bshara
- , Ahuva Grubstein
- , Ludmila Fridel
- , Tzippy Shochat
- , Laila C. Roisman
- , Maya Ilouze
- , Anna Belilovski Rozenblum
- , Smadar Geva
- , Alona Zer
- , Ofer Rotem
- , Aaron M. Allen
- , Nir Peled
*Corresponding author for this work
- Rabin Medical Center Israel
- Tel Aviv University
- Soroka Medical Center
- Ben-Gurion University of the Negev
Research output: Contribution to journal › Article › peer-review
61
Scopus
citations